2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alessandra Larocca, MD, PhD, discusses what to know when diagnosing difficult-to-treat patients with multiple myeloma.
Alessandra Larocca, MD, PhD, hematologist, Division of Hematology, University of Torino, Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di Torino, Italy, discusses what to know when diagnosing difficult-to-treat patients with multiple myeloma.
The prognosis for a patient with multiple myeloma can be defined by several factors, Larocca says. Patients could be categorized as difficult-to-treat for a variety of reasons, including the presence of high-risk chromosomal abnormalities or presentation with an aggressive disease, such as plasma cell leukemia or extramedullary disease, Larocca explains.
Patient-related factors can also play a role in the prognosis, Larocca continues. Age, frailty status, the presence of comorbidities, functional impairments, and organ function can all contribute in an individual patient’s prognosis, Larocca concludes.